Developing Next-Generation Medicines for Patients with Epilepsy and Other Neurological Diseases
Avata Biosciences, formerly Sapient Therapeutics Ltd., is a clinical-stage biopharmaceutical company with a mission to improve the lives of patients living with neurological disease with synthetic cannabinoids and a novel formulation process designed to address larger patient populations.
CANNABIDIOL (CBD)
MOVING BEYOND THE PLANT
NEXT-GENERATION PHARMACEUTICAL GRADE CANNABINOID MEDICINES
WATER SOLUBLE Formulations
SOLID DOSE Preparations
IMPROVED Bioavailability
SCALABLE Manufacturing to address large populations
OUR APPROACH
NEXT-GENERATION PHARMACEUTICAL GRADE CANNABINOID MEDICINES
Proprietary process that turns a water insoluble API into water soluble powder
Water soluble powder can be manufactured into capsules
Oil, alcohol and THC free
Treating Disease Where Significant Unmet Need Exists...
In Partnership with Oxford University for the improvement of Mental Health
And Delivering on a Robust Pipeline
PROGRAM
INDICATION
DISCOVERY
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
AVAT-021
Capsule
AVAT-022
Aqueous Solution
AVAT-021*
Capsule
AVAT-031
Solid Dose
AVAT-041
Solid Dose
Adult Focal Epilepsy
Pediatric Focal Epilepsy
Schizophrenia
Opioid Sparing
Addiction
*In Partnership with Oxford University for the improvement of Mental Health
OUR TEAM
Leaders in Cannabinoid Science, Medicine and Commercialization
Rupert Haynes
Chief Executive Officer
Dr. Andrew Saich
Chief Medical Officer
Rupert is a cofounder of Avata Biosciences and Chief Executive Officer. Before Avata, he led the strategic commercial development of GW Pharmaceuticals' cannabinoid portfolio in preparation for the commercial launch of Epidiolex®.
Andrew is a cofounder of Avata Biosciences and Chief Medical Officer. Prior to Avata, he created and led the GW Pharmaceuticals International Medical Organization preparing and supporting the launch of Epidiolex® and Sativex in Europe.
Venkat is an expert in cannabinoids and pharmaceutical formulations having developed prescription products from concept through to commercialization, with more than 22 years of experience in drug development.
Julian is a cofounder of Avata Biosciences and Executive Chairman. Prior to his current role, he founded infection control technology development pioneers Sterilox Technologies and PuriCore Plc.
Dr. Venkat Goskonda Ph.D.
Chief Scientific Officer
Julian Bryson
Executive Chairman
Grace Powell
Head of Regulatory Affairs
Grace leads Avata’s regulatory work, having previously supported the FDA filing for Epidiolex® in the US while at GW Pharmaceuticals Plc.
Chris leads Avata’s IP strategy. He was formerly Vice President & Global Head of IP at Jazz Pharmaceuticals and VP of IP at GW Pharmaceuticals Plc.
Dr. Chris Hayes
Head of Intellectual Property
Jim Gillespie
Program Director
Jim leads program management across Avata’s assets. He was the program leader for the global commercialization of Epidiolex® at GW Pharmaceuticals Plc. and commercial lead for the integration with Jazz Pharmaceuticals.
Dr. Emma Cheetham
Patent Portfolio Director
Emma leads Avata’s IP portfolio development, and was responsible for generating the patent portfolios for Epidiolex® at GW Pharmaceuticals Plc.
OUR TEAM
Scientific Advisors
Dr Johannes Roebers
Johannes is assisting Avata Biosciences in the development and implementation of a fully integrated CMC and manufacturing plan. Johannes has over 25 years of experience in R&D leadership, commercial scale manufacturing design, strategy development, engineering and regulatory affairs.
Professor Finbar O'Callaghan
Finbar is a Professor of Pediatric Neuroscience at the Institute of Child Health, University College London. He is a consultant pediatric neurologist at Great Ormond Street Hospital in London and advises Avata Biosciences on evolving treatment pathways in epilepsy and clinical trial design.
Professor Philip McGuire
Philip is a Professor of Psychiatry, Department of Psychiatry at the University of Oxford. He is advising Avata Biosciences on the clinical application of Avata’s clinical assets in psychiatric illness, initially schizophrenia.
MEDIA
LATEST NEWS
AND EVENTS
254 Park Av. South
New York, NY 10010
6 Stratton Street, Mayfair, London,
W1J 8LD
Level 7, 330 Collins Street Melbourne
VIC 3000
AVA-WEB102-August 2024
© 2024 Avata Biosciences Inc. All rights reserved.